BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $SNY readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07216079-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:rilzabrutinib readout (P3) · Sanofi $SNY
DESCRIPTION:Rilzabrutinib for the Adult Participants With Chronic ITP Who H
 ave Completed Phase 3 Study in Japan\n\nPrimary completion date: 2026-11-2
 5 (estimated)\nPhase 3 · Cardio-Met · Immune Thrombocytopenia\nEnrollmen
 t: 3 · Sites: 3\n\nPrimary completion = last participant's primary-endpoi
 nt data collected\; topline results usually follow weeks to months later. 
 Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://da
 tacutoff.com/radar.html?nct=NCT07216079\nhttps://clinicaltrials.gov/study/
 NCT07216079
URL:https://datacutoff.com/radar.html?nct=NCT07216079
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07103148-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261128
DTEND;VALUE=DATE:20261129
SUMMARY:Yellow fever vaccine (live) readout (P3) · Sanofi $SNY
DESCRIPTION:A Phase III Control Study of the Safety and Immunogenicity of v
 YF in Pediatric Population\n\nPrimary completion date: 2026-11-28 (estimat
 ed)\nOriginally planned: 2026-08-08 (+3.7 months)\nPhase 3 · Infectious 
 · Yellow Fever Immunization\nEnrollment: 2440 · Sites: 15\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT
 07103148\nhttps://clinicaltrials.gov/study/NCT07103148
URL:https://datacutoff.com/radar.html?nct=NCT07103148
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06838000-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:PCV21 readout (P3) · Sanofi Pasteur\, a Sanofi Company $SNY
DESCRIPTION:Study of the Safety and Immunogenicity of Catch-up Vaccination 
 With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants
 \, Toddlers\, Children\, and Adolescents\n\nPrimary completion date: 2026-
 12-01 (estimated)\nOriginally planned: 2026-06-01 (+6.0 months)\nPhase 3 
 · Infectious · Pneumococcal Infections\nEnrollment: 1268 · Sites: 38\n\
 nPrimary completion = last participant's primary-endpoint data collected\;
  topline results usually follow weeks to months later. Sponsor-reported\, 
 often an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.
 html?nct=NCT06838000\nhttps://clinicaltrials.gov/study/NCT06838000
URL:https://datacutoff.com/radar.html?nct=NCT06838000
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958536-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:CHROMA CD readout (P2) · Sanofi $SNY
DESCRIPTION:A Study to Investigate Efficacy and Safety of Brivekimig in Par
 ticipants With Crohn's Disease\n\nPrimary completion date: 2026-12-17 (est
 imated)\nPhase 2 · GI·Renal·Heme · Crohn's Disease\nEnrollment: 99 · 
 Sites: 78\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://datacutof
 f.com/radar.html?nct=NCT06958536\nhttps://clinicaltrials.gov/study/NCT0695
 8536
URL:https://datacutoff.com/radar.html?nct=NCT06958536
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975722-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:COLOR UC readout (P2) · Sanofi $SNY
DESCRIPTION:A Study to Investigate the Efficacy and Safety of Brivekimig in
  Adult Participants With Ulcerative Colitis\n\nPrimary completion date: 20
 26-12-17 (estimated)\nPhase 2 · GI·Renal·Heme · Ulcerative Colitis\nEn
 rollment: 105 · Sites: 69\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://datacutoff.com/radar.html?nct=NCT06975722\nhttps://clinicaltrials.
 gov/study/NCT06975722
URL:https://datacutoff.com/radar.html?nct=NCT06975722
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500702-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:RESULT readout (P2) · Sanofi $SNY
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Frexalimab\, Bri
 vekimig\, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primar
 y Focal Segmental Glomerulosclerosis or Mini…\n\nPrimary completion date
 : 2026-12-23 (estimated)\nPhase 2 · GI·Renal·Heme · Focal Segmental Gl
 omerulosclerosis\, Glomerulonephritis Minimal Lesion\nEnrollment: 84 · Si
 tes: 82\n\nPrimary completion = last participant's primary-endpoint data c
 ollected\; topline results usually follow weeks to months later. Sponsor-r
 eported\, often an estimate. Not investment advice.\n\nhttps://datacutoff.
 com/radar.html?nct=NCT06500702\nhttps://clinicaltrials.gov/study/NCT065007
 02
URL:https://datacutoff.com/radar.html?nct=NCT06500702
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247188-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270107
DTEND;VALUE=DATE:20270108
SUMMARY:PCV21 readout (P3) · Sanofi $SNY
DESCRIPTION:Study of a Single Dose of a 21-valent Pneumococcal Conjugate Va
 ccine in Children and Adolescents With Sickle Cell Disease\n\nPrimary comp
 letion date: 2027-01-07 (estimated)\nPhase 3 · Rare · Sickle Cell Diseas
 e\nEnrollment: 100 · Sites: 7\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://datacutoff.com/radar.html?nct=NCT07247188\nhttps://clinicaltri
 als.gov/study/NCT07247188
URL:https://datacutoff.com/radar.html?nct=NCT07247188
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170917-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:BRIGHTEN readout (P2) · Sanofi $SNY
DESCRIPTION:Brivekimig for the Treatment of Moderate to Severe Hidradenitis
  Suppurativa\n\nPrimary completion date: 2027-02-09 (estimated)\nOriginall
 y planned: 2027-08-01 (-5.7 months)\nPhase 2 · Infectious · Hidradenitis
  Suppurativa\nEnrollment: 208 · Sites: 85\n\nPrimary completion = last pa
 rticipant's primary-endpoint data collected\; topline results usually foll
 ow weeks to months later. Sponsor-reported\, often an estimate. Not invest
 ment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07170917\nhttps:/
 /clinicaltrials.gov/study/NCT07170917
URL:https://datacutoff.com/radar.html?nct=NCT07170917
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06984627-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:Rilzabrutinib dose 1 readout (P2) · Sanofi $SNY
DESCRIPTION:A Study to Investigate the Efficacy and Safety of Rilzabrutinib
  in Adult Participants With Graves' Disease\n\nPrimary completion date: 20
 27-02-11 (estimated)\nOriginally planned: 2026-08-25 (+5.6 months)\nPhase 
 2 · Cardio-Met · Graves' Disease\nEnrollment: 30 · Sites: 24\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct
 =NCT06984627\nhttps://clinicaltrials.gov/study/NCT06984627
URL:https://datacutoff.com/radar.html?nct=NCT06984627
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424144-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:CEREN-3 readout (P3) · Sanofi $SNY
DESCRIPTION:An Extension Study to Investigate the Long-term Safety and Tole
 rability of Itepekimab in Adult Participants With Inadequately Controlled 
 Chronic Rhinosinusitis With Nasal Polyps\n\nPrimary completion date: 2027-
 02-17 (estimated)\nOriginally planned: 2028-12-12 (-21.8 months)\nPhase 3 
 · Other · Chronic Rhinosinusitis With Nasal Polyps\nEnrollment: 59 · Si
 tes: 46\n\nPrimary completion = last participant's primary-endpoint data c
 ollected\; topline results usually follow weeks to months later. Sponsor-r
 eported\, often an estimate. Not investment advice.\n\nhttps://datacutoff.
 com/radar.html?nct=NCT07424144\nhttps://clinicaltrials.gov/study/NCT074241
 44
URL:https://datacutoff.com/radar.html?nct=NCT07424144
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05662319-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:ATLAS-NEO readout (P3) · Sanofi $SNY
DESCRIPTION:A Study to Test a Medicine (Fitusiran) Injected Under the Skin 
 for Preventing Bleeding Episodes in Male Adolescent or Adult Participants 
 With Severe Hemophilia\n\nPrimary completion date: 2027-03-25 (estimated)\
 nOriginally planned: 2026-04-15 (+11.3 months)\nPhase 3 · Rare · Hemophi
 lia\nEnrollment: 91 · Sites: 50\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://datacutoff.com/radar.html?nct=NCT05662319\nhttps://clinicalt
 rials.gov/study/NCT05662319
URL:https://datacutoff.com/radar.html?nct=NCT05662319
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356571-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:SubQSA readout (P2) · Sanofi $SNY
DESCRIPTION:A Study to Investigate Subcutaneous Isatuximab in Combination W
 ith Weekly Carfilzomib and Dexamethasone in Adult Participants With Relaps
 ed and/or Refractory Multiple Myeloma\n\nPrimary completion date: 2027-04-
 01 (estimated)\nOriginally planned: 2027-01-08 (+2.7 months)\nPhase 2 · O
 ncology · Plasma Cell Myeloma Refractory\nEnrollment: 64 · Sites: 34\n\n
 Primary completion = last participant's primary-endpoint data collected\; 
 topline results usually follow weeks to months later. Sponsor-reported\, o
 ften an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.h
 tml?nct=NCT06356571\nhttps://clinicaltrials.gov/study/NCT06356571
URL:https://datacutoff.com/radar.html?nct=NCT06356571
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:IMROZ readout (P3) · Sanofi $SNY
DESCRIPTION:A Study to Investigate the Clinical Benefit of Isatuximab in Co
 mbination With Bortezomib\, Lenalidomide and Dexamethasone in Adults With 
 Newly Diagnosed Multiple Myeloma Not Eligib…\n\nPrimary completion date:
  2027-04-05 (estimated)\nOriginally planned: 2022-12 (+52.1 months)\nPhase
  3 · Oncology · Plasma Cell Myeloma\nEnrollment: 475 · Sites: 104\n\nPr
 imary completion = last participant's primary-endpoint data collected\; to
 pline results usually follow weeks to months later. Sponsor-reported\, oft
 en an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.htm
 l?nct=NCT03319667\nhttps://clinicaltrials.gov/study/NCT03319667
URL:https://datacutoff.com/radar.html?nct=NCT03319667
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156175-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270408
DTEND;VALUE=DATE:20270409
SUMMARY:SAR444336 readout (P2) · Sanofi $SNY
DESCRIPTION:A Study to Investigate the Efficacy and Safety of SAR444336 in 
 Adults With Microscopic Colitis in Clinical Remission\n\nPrimary completio
 n date: 2027-04-08 (estimated)\nPhase 2 · GI·Renal·Heme · Microscopic 
 Colitis\nEnrollment: 60 · Sites: 24\n\nPrimary completion = last particip
 ant's primary-endpoint data collected\; topline results usually follow wee
 ks to months later. Sponsor-reported\, often an estimate. Not investment a
 dvice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07156175\nhttps://clini
 caltrials.gov/study/NCT07156175
URL:https://datacutoff.com/radar.html?nct=NCT07156175
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06111586-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:FABULINUS readout (P2) · Sanofi $SNY
DESCRIPTION:Frexalimab in Preservation of Endogenous Insulin Secretion Comp
 ared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABUL
 INUS)\n\nPrimary completion date: 2027-04-28 (estimated)\nPhase 2 · Cardi
 o-Met · Type 1 Diabetes Mellitus\nEnrollment: 197 · Sites: 79\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct
 =NCT06111586\nhttps://clinicaltrials.gov/study/NCT06111586
URL:https://datacutoff.com/radar.html?nct=NCT06111586
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06812988-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:T1D OBTAIN readout (P2) · Sanofi $SNY
DESCRIPTION:Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With An
 ti-TNF Activity In a Single Nanobody® Molecule\n\nPrimary completion date
 : 2027-04-29 (estimated)\nOriginally planned: 2027-08-09 (-3.4 months)\nPh
 ase 2 · Cardio-Met · Type 1 Diabetes Mellitus\nEnrollment: 84 · Sites: 
 24\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/r
 adar.html?nct=NCT06812988\nhttps://clinicaltrials.gov/study/NCT06812988
URL:https://datacutoff.com/radar.html?nct=NCT06812988
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141473-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270506
DTEND;VALUE=DATE:20270507
SUMMARY:FREXALT readout (P3) · Sanofi $SNY
DESCRIPTION:Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults
  With Relapsing Forms of Multiple Sclerosis\n\nPrimary completion date: 20
 27-05-06 (estimated)\nPhase 3 · Neuro · Multiple Sclerosis\nEnrollment: 
 1655 · Sites: 382\n\nPrimary completion = last participant's primary-endp
 oint data collected\; topline results usually follow weeks to months later
 . Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://
 datacutoff.com/radar.html?nct=NCT06141473\nhttps://clinicaltrials.gov/stud
 y/NCT06141473
URL:https://datacutoff.com/radar.html?nct=NCT06141473
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06736041-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:PCV21 vaccine readout (P3) · Sanofi Pasteur\, a Sanofi Company $SN
 Y
DESCRIPTION:Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate
  Vaccine in Healthy Infants From Approximately 2 Months of Age\n\nPrimary 
 completion date: 2027-05-17 (estimated)\nPhase 3 · Infectious · Pneumoco
 ccal Immunization\nEnrollment: 1714 · Sites: 112\n\nPrimary completion = 
 last participant's primary-endpoint data collected\; topline results usual
 ly follow weeks to months later. Sponsor-reported\, often an estimate. Not
  investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06736041\n
 https://clinicaltrials.gov/study/NCT06736041
URL:https://datacutoff.com/radar.html?nct=NCT06736041
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05263206-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270602
DTEND;VALUE=DATE:20270603
SUMMARY:Dupilumab readout (P3) · Sanofi $SNY
DESCRIPTION:Efficacy and Safety of Subcutaneous Dupilumab for the Treatment
  of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIB
 ERTY-CPUO-CHIC)\n\nPrimary completion date: 2027-06-02 (estimated)\nOrigin
 ally planned: 2025-03-21 (+26.4 months)\nPhase 3 · Immuno · Pruritus\nEn
 rollment: 284 · Sites: 94\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://datacutoff.com/radar.html?nct=NCT05263206\nhttps://clinicaltrials.
 gov/study/NCT05263206
URL:https://datacutoff.com/radar.html?nct=NCT05263206
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348692-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270607
DTEND;VALUE=DATE:20270608
SUMMARY:PCV21 vaccine readout (P3) · Sanofi $SNY
DESCRIPTION:Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjug
 ate Vaccine in Healthy Infants From 2 Months of Age\n\nPrimary completion 
 date: 2027-06-07 (estimated)\nOriginally planned: 2028-01-19 (-7.4 months)
 \nPhase 3 · Infectious · Pneumococcal Immunization\, Healthy Volunteers\
 nEnrollment: 2195 · Sites: 25\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://datacutoff.com/radar.html?nct=NCT07348692\nhttps://clinicaltri
 als.gov/study/NCT07348692
URL:https://datacutoff.com/radar.html?nct=NCT07348692
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676319-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:AIRLYMPUS readout (P2) · Sanofi $SNY
DESCRIPTION:Study of Lunsekimig (SAR443765) Compared With Placebo in Adults
  With High-risk Asthma\n\nPrimary completion date: 2027-06-21 (estimated)\
 nOriginally planned: 2027-10-12 (-3.7 months)\nPhase 2 · Respiratory · A
 sthma\nEnrollment: 556 · Sites: 221\n\nPrimary completion = last particip
 ant's primary-endpoint data collected\; topline results usually follow wee
 ks to months later. Sponsor-reported\, often an estimate. Not investment a
 dvice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06676319\nhttps://clini
 caltrials.gov/study/NCT06676319
URL:https://datacutoff.com/radar.html?nct=NCT06676319
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06290141-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:VITALIZE readout (P3) · Sanofi $SNY
DESCRIPTION:A Study to Test the Efficacy and Safety of Riliprubart Against 
 the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Ch
 ronic Inflammatory Demyelinating Polyneuro…\n\nPrimary completion date: 
 2027-07-09 (estimated)\nOriginally planned: 2025-11-05 (+20.1 months)\nPha
 se 3 · Neuro · Chronic Inflammatory Demyelinating Polyneuropathy\nEnroll
 ment: 160 · Sites: 138\n\nPrimary completion = last participant's primary
 -endpoint data collected\; topline results usually follow weeks to months 
 later. Sponsor-reported\, often an estimate. Not investment advice.\n\nhtt
 ps://datacutoff.com/radar.html?nct=NCT06290141\nhttps://clinicaltrials.gov
 /study/NCT06290141
URL:https://datacutoff.com/radar.html?nct=NCT06290141
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325292-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Frexcite readout (P3) · Sanofi $SNY
DESCRIPTION:Non-inferiority Study of Frexalimab Subcutaneous Administration
  Compared to Intravenous Administration in Adult Participants With Multipl
 e Sclerosis\n\nPrimary completion date: 2027-07-15 (estimated)\nPhase 3 ·
  Neuro · Multiple Sclerosis\nEnrollment: 160 · Sites: 68\n\nPrimary comp
 letion = last participant's primary-endpoint data collected\; topline resu
 lts usually follow weeks to months later. Sponsor-reported\, often an esti
 mate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0
 7325292\nhttps://clinicaltrials.gov/study/NCT07325292
URL:https://datacutoff.com/radar.html?nct=NCT07325292
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975865-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270723
DTEND;VALUE=DATE:20270724
SUMMARY:LIBRA readout (P3) · Sanofi $SNY
DESCRIPTION:The Efficacy and Safety of Rilzabrutinib in Participants Aged 1
 0 to 65 Years With Sickle-cell Disease\n\nPrimary completion date: 2027-07
 -23 (estimated)\nPhase 3 · Rare · Sickle Cell Disease\nEnrollment: 192 
 · Sites: 64\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://datacu
 toff.com/radar.html?nct=NCT06975865\nhttps://clinicaltrials.gov/study/NCT0
 6975865
URL:https://datacutoff.com/radar.html?nct=NCT06975865
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975878-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:PCV21 vaccine readout (P3) · Sanofi $SNY
DESCRIPTION:Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy 
 Infants From Approximately 2 Months of Age\n\nPrimary completion date: 202
 7-08-25 (estimated)\nPhase 3 · Infectious · Pneumococcal Immunization\, 
 Healthy Volunteers\nEnrollment: 1092 · Sites: 49\n\nPrimary completion = 
 last participant's primary-endpoint data collected\; topline results usual
 ly follow weeks to months later. Sponsor-reported\, often an estimate. Not
  investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06975878\n
 https://clinicaltrials.gov/study/NCT06975878
URL:https://datacutoff.com/radar.html?nct=NCT06975878
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824181-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:PCV21 vaccine readout (P3) · Sanofi $SNY
DESCRIPTION:Study of Mixed Vaccination Schedules With a 21-valent Pneumococ
 cal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in He
 althy Infants From Approximately 2 Months …\n\nPrimary completion date: 
 2027-09-10 (estimated)\nOriginally planned: 2027-05-17 (+3.8 months)\nPhas
 e 3 · Infectious · Pneumococcal Immunization\nEnrollment: 580 · Sites: 
 27\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/r
 adar.html?nct=NCT06824181\nhttps://clinicaltrials.gov/study/NCT06824181
URL:https://datacutoff.com/radar.html?nct=NCT06824181
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225569-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270922
DTEND;VALUE=DATE:20270923
SUMMARY:CLAROS readout (P2) · Sanofi $SNY
DESCRIPTION:A Study to Investigate Efficacy and Safety With SAR445399 in Ad
 ult Participants With Moderate to Severe Hidradenitis Suppurativa\n\nPrima
 ry completion date: 2027-09-22 (estimated)\nPhase 2 · Infectious · Hidra
 denitis Suppurativa\nEnrollment: 144 · Sites: 86\n\nPrimary completion = 
 last participant's primary-endpoint data collected\; topline results usual
 ly follow weeks to months later. Sponsor-reported\, often an estimate. Not
  investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07225569\n
 https://clinicaltrials.gov/study/NCT07225569
URL:https://datacutoff.com/radar.html?nct=NCT07225569
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06241118-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:AQUA readout (P3) · Sanofi $SNY
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Subcutaneous Aml
 itelimab on Background Topical Corticosteroids Therapy in Participants Age
 d 12 Years and Older With Moderate-to-seve…\n\nPrimary completion date: 
 2027-09-30 (estimated)\nOriginally planned: 2026-03-20 (+18.4 months)\nPha
 se 3 · Immuno · Dermatitis Atopic\nEnrollment: 464 · Sites: 154\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT06241118\nhttps://clinicaltrials.gov/study/NCT06241118
URL:https://datacutoff.com/radar.html?nct=NCT06241118
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824194-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271022
DTEND;VALUE=DATE:20271023
SUMMARY:PCV21 vaccine readout (P3) · Sanofi $SNY
DESCRIPTION:Study of the Safety of a 21-valent Pneumococcal Conjugate Vacci
 ne in Healthy Infants From Approximately 2 Months of Age\n\nPrimary comple
 tion date: 2027-10-22 (estimated)\nOriginally planned: 2027-05-12 (+5.4 mo
 nths)\nPhase 3 · Infectious · Pneumococcal Immunization\nEnrollment: 236
 0 · Sites: 132\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://dat
 acutoff.com/radar.html?nct=NCT06824194\nhttps://clinicaltrials.gov/study/N
 CT06824194
URL:https://datacutoff.com/radar.html?nct=NCT06824194
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06293053-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Dupilumab readout (P3) · Sanofi $SNY
DESCRIPTION:A Study to Investigate the Pharmacokinetics and Safety of Dupil
 umab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodulari
 s\n\nPrimary completion date: 2027-10-28 (estimated)\nPhase 3 · Immuno ·
  Prurigo Nodularis\nEnrollment: 18 · Sites: 15\n\nPrimary completion = la
 st participant's primary-endpoint data collected\; topline results usually
  follow weeks to months later. Sponsor-reported\, often an estimate. Not i
 nvestment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06293053\nht
 tps://clinicaltrials.gov/study/NCT06293053
URL:https://datacutoff.com/radar.html?nct=NCT06293053
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007962-pcd@datacutoff.com
DTSTAMP:20261118T140728Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:LUNA 4 readout (P3) · Sanofi $SNY
DESCRIPTION:Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib
  in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatm
 ent\n\nPrimary completion date: 2027-11-05 (estimated)\nPhase 3 · Cardio-
 Met · Immune Thrombocytopenia\nEnrollment: 60 · Sites: 54\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT
 07007962\nhttps://clinicaltrials.gov/study/NCT07007962
URL:https://datacutoff.com/radar.html?nct=NCT07007962
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
